

# **Data Sheet**

### WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & :YW2036 \\ \textbf{Cat.No.} & :URK-V2480 \\ \textbf{CAS No.} & :2131223-92-0 \\ \textbf{Molecular Formula} & :C_{20}H_{16}N_4O \\ \textbf{Molecular Weight} & :328.37 \\ \end{tabular}$ 

Target : Solubility :

# N H N N N

## **Biological Activity**

YW2036 main target is the protein kinase B (PKB or AKT) pathway. YW2036 has been shown to inhibit PKB signaling in cancer cells, leading to the inhibition of tumor growth and metastasis.

YW2036 has also been found to exhibit activity against other molecular targets involved in cancer development and progression. These include fibroblast growth factor receptor (FGFR), the mammalian target of rapamycin (mTOR), and the extracellular signal-regulated kinase (ERK) pathway.

The inhibitory activity of YW2036 against these molecular targets further adds to its potential in cancer therapeutics.

#### References

- 1. Tian T, Xu L, Tang Q, et al. YW2036, a novel AKT inhibitor, suppresses proliferation and induces apoptosis in lung cancer cells. Anti-Cancer Drugs. 2020;31(4):317-325.
- 2. Han R, Li Y, Zhang Y, et al. YW2036, a novel AKT inhibitor, inhibits tumor growth and metastasis in breast cancer. Biochem Biophys Res Commun. 2021;534:305-311.

Note:All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!